stockmarketproxy
/
GILDNasdaq SEC EDGAR

GILEAD SCIENCES, INC.

Biological Products, (No Diagnostic Substances)·FOSTER CITY, CA·FY end 12/31·CIK 882095
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$29.4B$28.8B$27.1B$27.3B$27.3B
Gross Profit——————
Operating Income$10.0B$1.7B$7.6B$7.3B$9.9B
Net Income$8.5B$480.0M$5.7B$4.6B$6.2B
Operating CF$10.0B$10.8B$8.0B$9.1B$11.4B
Capex$563.0M$523.0M$585.0M$728.0M$579.0M
Free Cash Flow$9.5B$10.3B$7.4B$8.3B$10.8B
Buybacks$1.9B$1.1B$1.0B$1.4B$546.0M
Dividends——————
Gross Margin——————
Operating Margin34.0%5.8%28.0%26.9%36.3%
Net Margin28.9%1.7%20.9%16.8%22.8%
FCF Margin32.1%35.8%27.4%30.6%39.6%
R&D / Revenue——————
Effective Tax13.1%30.6%18.2%21.5%25.1%
Debt / Equity2.072.672.112.272.46
Buybacks / FCF20.3%11.2%13.5%16.7%5.1%

Peer comparison

Biological Products, (No Diagnostic Substances) · 5 peers
CEO Pay Ratio
GILD
119:1
EXEL
81:1
BIIB
113:1
PCVX
48:1
IBRX
69:1
CGON
6:1
CEO total comp
GILD
$28M
EXEL
$33M
BIIB
$24M
PCVX
$14M
IBRX
$13M
CGON
$12M
Net Margin
GILD
28.9%
EXEL
33.7%
BIIB
13.1%
PCVX
—
IBRX
-310.2%
CGON
—